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Abstract
Background: Metastasis-associated in colon cancer 1 (MACC1) is demonstrated to be up-regulated in several types
of cancer, and can serve as biomarker for cancer invasion and metastasis. To investigate the relations between
MACC1 and biological processes of ovarian cancer, MACC1 specific small hairpin RNA (shRNA) expression plasmids
were used to investigate the effects of MACC1 inhibition on ovarian carcinoma OVCAR-3 cells.
Methods: Expressions of MACC1 were detected in different ovarian tissues by immunohistochemistry. MACC1
specific shRNA expression plasmids were constructed and transfected into OVCAR-3 cells. Then, expressions of
MACC1 were examined by reverse transcription polymerase chain reaction (RT-PCR) and Western blot. Cell
proliferation was observed by MTT and monoplast colony formation assay. Flow cytometry and TUNEL assay were
used to measure cell apoptosis. Cell migration was assessed by wound healing and transwell migration assay.
Matrigel invasion and xenograft model assay were performed to analyze the potential of cell invasion. Activities of
Met, MEK1/2, ERK1/2, Akt, cyclinD1, caspase3 and MMP2 protein were measured by Western blot.
Results: Overexpressions of MACC1 were detected in ovarian cancer tissues. Expression of MACC1 in OVCAR-3 cells
was significantly down-regulated by MACC1 specific small hairpin RNA. In OVCAR-3 cells, down-regulation of
MACC1 resulted in significant inhibition of cell proliferation, migration and invasion, meanwhile obvious
enhancement of apoptosis. As a consequence of MACC1 knockdown, expressions of Met, p-MEK1/2, p-ERK1/2,
cyclinD1 and MMP2 protein decreased, level of cleaved capase3 was increased.
Conclusions: RNA interference (RNAi) against MACC1 could serve as a promising intervention strategy for gene
therapy of ovarian carcinoma, and the antitumor effects of MACC1 knockdown might involve in the inhibition of
HGF/Met and MEK/ERK pathways.
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Background
Ovarian cancer is one of malignant tumors in female geni-
tal system, but is the leading cause of death from gyneco-
logical cancer in the world [1]. Despite improvements in
the application of aggressive cytoreductive surgery and
combination chemotherapy, ovarian cancer has the most
unfavorable prognosis due to its insidious onset, diagnosis
at late stage, dissemination, relapse, and tendency to
develop chemotherapy resistance. Though considerable
efforts aim at elucidating the tumorigenesis of ovarian car-
cinoma, its molecular mechanism has not been completely
explained.
Recently, MACC1 has been identified as a prognosis
biomarker for colon cancer, which promotes prolifera-
tion, invasion and hepatocyte growth factor (HGF)-
induced scattering of colon cancer cells in vitro and in
vivo [2]. MET, which encodes Met protein, has been pro-
ven to be a transcriptional target of MACC1. MACC1
controls the activity and expression of MET, and regu-
lates HGF/Met signal pathway [2]. HGF/Met pathway
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any medium, provided the original work is properly cited.plays key roles in carcinogenesis, aberrant activation of
Met leads to enhancement of cell proliferation, invasion
and metastasis, and Met is essential for metastatic poten-
tial of many malignances [3]. Once activated by HGF,
Met transmits intracellular signals and activates down-
stream Ras-mitogen-activated protein kinase (MAPK)
and phosphoinositide 3-kinase (PI3K)/Akt pathways,
which promote cell survival, migration, invasion, and
suppress apoptosis [4].
MACC1 was demonstrated to be associated with poor
prognosis and high risk of metastasis in colon cancer, gas-
tric carcinoma, lung cancer, and hepatocellular carcinoma
[5-8]. However, the mechanism of MACC1 implicates in
ovarian cancer is still unclear. Small interfering RNA can
specifically silence particular genes, and is used as a
powerful tool to research gene functions and as a genetic
therapy strategy for carcinoma [9]. In present study,
expressions of MACC1 were detected in different ovarian
tissues by immunohistochemistry, effects of MACC1 inhi-
bition on OVCAR-3 cells were observed by RNA interfer-
ence, and the possible antitumor mechanisms of MACC1
knockdown in ovarian carcinoma cells were discussed.
Materials and methods
Immunohistochemistry and evaluation
Paraffin-embedded 20 specimens of normal ovary, 19
specimens of benign ovarian tumor and 52 specimens of
ovarian cancer tissues were obtained from Department of
Pathology of Zhengzhou University. Rabbit-anti-human
polyclonal MACC1 antibody (Sigma, USA) was used for
immunohistochemistry assay, which was performed fol-
lowing the protocol of Universal SP kit (Zhongshan
Goldenbridge Biotechnology, Peking, China). Positive
staining of MACC1 protein presents brown in cytoplasm,
partly in nucleus. Semi-quantitative counting method
was used to determine positive staining described as fol-
lowing: Selected 10 visual fields under high power lens
(× 400) randomly, counted the numbers of positive cells
in 100 cells per field, calculated the average positive rate.
Positive rate less than 1/3 scored as 1, more than 1/3 and
less than 2/3 scored as 2, more than 2/3 scored as 3,
without positive cell scored as 0. Cells without brown
staining scored as 0, with mild brown staining scored as
1, with moderate brown staining scored as 2, with intense
brown staining scored as 3. The final positive scores =
positive rate score × staining intensity score, 0 score was
negative staining (-), 1~4 scores were positive staining
(+), more than 4 scores was strong positive (++).
ShRNAs synthesis and plasmids construction
Single shRNA strands were 5’-GATCCCC-N21-TTCAA-
GAGA-N’21-TTTTTGGA-AA-3’ (sense) and 5’-AGCTT
TTCCAAAAA-N21-TCTCTTGAAN’21-GGG-3’ (anti-
sense). N21 was the sense sequence of MACC1 target
oligonucleotides, N’21 was antisense sequence of MACC1
target oligonucleotides. Three different template oligonu-
cleotides targeting MACC1 [GeneBank, NM_182762.3]
were as follow: MACC1-s1, 5’-AAAGACAGAAGGA-
GAAAGGAA-3’; MACC1-s2, 5’-AATCAAC-
TGTCTGCTTCTAAC-3’;M A C C 1 - s 3 ,5 ’-AATTA-
TATGCCAGGACAGCTT-3’. As a negative control, one
scrambled sequence 5’-AACAGTTATCTATGCGA-
CAGT-3’ (corresponding to MACC1-s3) was designed.
These sequences were submitted to BLAST against
human genome sequence to ensure that only MACC1
gene was targeted. All single shRNA strands were synthe-
sized at Sangon Biotechnology Co., Ltd (Shanghai,
China), and were annealed and ligated into the BglII and
HindIII sites of linearized psuper-EGFP plasmid. The
four shRNAs inserted vectors were named as psuper-
EGFP-s1, psuper-EGFP-s2, psuper-EGFP-s3, and psuper-
EGFP-NC respectively.
Cell transfection
Human ovarian carcinoma OVCAR-3 cells (with high level
of MACC1 expression measured in our preliminary study)
were purchased from Chinese Academy of Sciences Cell
Bank (Shanghai, China), and cultured in DMEM medium
(HyClone, USA) supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin and 100 mg/ml strepto-
mycin at 37°C with 5% CO2. Cells were harvested in loga-
rithmic phase of growth for all experiments described
below. Cell transfection was performed following the pro-
tocol of Lipofectamine 2000 (Invitrogen, USA). The
untransfected cells, empty vector (psuper-EGFP-neo) trans-
fected cells, and nonspecific shRNA (psuper-EGFP-NC)
transfected cells were used as controls. Stably transfected
OVCAR-3 cells were selected with 800 μg/ml G418
(Sigma, USA) after tansfection 48 h. After 12 days, resistant
colonies were trypsinized and cultured in selective med-
ium. Names of the stably transfected cells were OVCAR-3-
neo, OVCAR-3-NC, OVCAR-3-s1, OVCAR-3-s2, and
OVCAR-3-s3 respectively.
RT-PCR
Cell total RNA was isolated using Trizol Reagent (Invitro-
gen, USA), and first strand cDNA was synthesized from 1
μg total RNA according to the protocol of RevertAid first
strand cDNA synthesis kit (Fermentas, EU). Primers used
in RT-PCR were as follow: MACC1, 5’-CCTTCGTGG
TAATAATGCTTCC-3’ (sense) and 5’-AGGGCTTC-
CATTGTATTGAGGT-3’ (antisense); b-actin, 5’-ACGC
ACC- CCAACTACAACTC-3’ (sense) and 5’-TCTCCTT
AATGTCACGCACGA-3’ (antisense). PCR cycling para-
meters (19 cycles) were: denaturation (94°C, 30s), anneal-
ing (56°C, 30s) and extension (72°C, 30s). Equal amounts
of PCR products were electrophoresed on 1.2% agarose
gels and visualized by ethidium bromide staining. The
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Pro Plus 6.0 system, b-actin was used as a control for nor-
malization. RT-PCR was performed for three times
independently.
Western blot
Primary antibodies used in Western blot, following manu-
facturer’s protocols, were anti-MACC1 (Sigma, USA),
anti-Met, anti-p-MEK1/2(ser212/ser218), anti-MEK1/2,
anti-p-ERK1/2(Thr202/Tyr204), anti-ERK1/2 and anti-
MMP2 (Santa Cruz, USA), anti-Akt, anti-p-Akt(Thr308),
anti-cyclinD1, anti-cleaved caspase3 and anti-b-actin
(Beyotime Biotechnology, Jiangsu, China). Total protein
was extracted using Cell Lysis Buffer for Western and IP
(Beyotime Biotechnology, Jiangsu, China), and protein
concentration was determined using Bradford assay. Equal
amounts of protein (30 μg) were separated by 10% SDS-
PAGE and transferred onto PVDF membranes. The detec-
tion of hybridized protein was performed by enhanced
chemiluminescence kit (Zhongshan Goldenbridge Biotech-
nology, Peking, China), b- a c t i nw a su s e da sac o n t r o lf o r
normalization. The specific bands were analyzed by
Image-Pro Plus 6.0 system.
MTT assay
Planted 2 × 10
4 cells per well into 96-well plates, and
added 100 μl medium containing 10% FBS into each well.
Five duplicate wells were set up for each group. Cultured
cells continuously for 7 days, added 20 μl MTT reagent
(5 mg/ml, Sigma, USA) into each well, incubated for
another 4 h then aspirated former medium and added
150 μl DMSO. The absorbance of sample was measured
by Microplate spectrophotometer (Thermo, USA) at
492 nm. All experiments were done in triplicate. Cell
growth curve was plotted versus time by origin 8 software.
Monoplast colony formation assay
Prepared single cell suspension, seeded about 50, 100,
200 cells of each group into 6-well plates respectively.
Added 2 ml medium containing 10% FBS into each well,
cultured cells continuously for one week. Fixated cells
with methanol for 5 min, stained cells by hematoxylin for
30 min, counted the numbers of colony (more than 10
cells per colony) under low power lens (× 100) of
inverted microscope (OLYMPU S ,I X 7 1 ,J a p a n ) ,a n dc a l -
culated the rate of colony formation.
Flow cytometry analysis
About 1 × 10
6 cells were treated into single cell suspen-
sion with PBS solution, and were prepared following
manufacture’s protocol of Annexin V-FITC Apoptosis
Detection Kit (Beyotime Biotechnology, Jiangsu, China).
Then, rates of apoptosis were analyzed with FACScan
system (BD, USA).
TUNEL assay
Dripped single cell suspension onto microscopic slides,
incubated cells for 4 h till cells were adherent. Three
duplicate slides were set up for each group. Fixated
cells by 4% paraformaldehyde for 30 min, blocked cells
by 0.3% H2O2 for 30 min, incubated cells with 0.1%
Triton X-100 for 2 min, then performed following man-
ufacture’s protocol of In situ cell death detection kit
(Roche, German). Selected five visual fields under high
power lens (× 400) randomly, counted the numbers of
apoptotic body in 100 cells, calculated the rate of
apoptosis.
Wound healing assay
About 5 × 10
4~1 × 10
5 cells were seeded into each well
of 6-well plates, three duplicate wells were set up for
each group, monolayer cells were obtained after cells
confluence. Scratched monolayer cells with 200 μl pipette
tip, washed cells 3 times with PBS, and added 2 ml med-
ium without FBS into each well. The values of scratch
were measured at 0 h and 24 h after scratching by Image
Pro-Plus 6.0 system.
Transwell migration assay
Transwell chambers (8 μm pore size; Millipore, USA) were
also used to measure cell migration. Seeded 2 × 10
5 cells
into each upper chamber with 200 μl fresh medium with-
out FBS, added 500 μl medium with 20% FBS into each
lower chamber, three duplicate wells were set up for each
group. After 12 h, fixated cells with methanol for 5 min,
and stained cells by hematoxylin for 30 min. Cleaned
upper chamber and inverted the chamber, counted cell
numbers on the lower membrane under high power lens
(× 400) in five random visual fields.
Matrigel invasion assay
Transwell chamber (8 μm pore size; Millipore, USA) cov-
ered with 100 μl of 1 mg/ml Matrigel (BD, USA) was used
to measure cell invasive ability. Seeded 1 × 10
5 cells into
each upper chamber with 200 μl fresh medium without
FBS, added 500 μl medium with 20% FBS into each lower
chamber, three duplicate wells were set up for each group.
After 12 h, fixated cells with methanol for 5 min, and
stained cells by hematoxylin for 30 min. Cleaned upper
chamber and inverted the chamber, counted cell numbers
on the lower membrane under high power lens (× 400) in
five random visual fields.
Xenograft model assay
The experimental protocol was approved by Zhengzhou
University Ethics Committee for Animal Experimentation.
Female BALB/c nu/nu mice (4-5 weeks old, 13-17 g) were
purchased from Vital River Laboratory Animal Technol-
ogy Co., Ltd (Peking, China), and were randomly assigned
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7
cells were suspended in 0.2 ml PBS and injected subcuta-
neously into one mouse. The tumors were monitored
every 5 days beginning at day 5 by measuring two perpen-
dicular diameters with a caliper. The mice were sacrificed
on the 35th day after injection, tumors were dissected and
measured, and tumor volume in mm
3 was calculated by
the formula: volume = (width)
2 ×l e n g t h / 2[ 1 0 ] .
Statistical analysis
Average values were expressed as mean ± standard
deviation (SD). Count data were analyzed by c
2 test.
Measurement data were analyzed by one-way ANOVA
and Bonferroni test using SPSS 17.0 software package.
Difference was considered significant when P value was
less than 0.05.
Results
Overexpressions of MACC1 in ovarian cancer tissues
The positive rates of MACC1 in normal ovary, benign
ovarian tumor and ovarian cancer tissues were detected
by immunohistochemistry (Table 1). Compared to nor-
mal ovary and benign ovarian tumor, expressions of
MACC1 were obviously up-regulated in ovarian cancer
tissues (Figure 1), which showed abnormal expression of
MACC1 might be associated with ovarian cancer.
Down-regulation of MACC1 expressions by RNAi
After transfection 48 h, transfected cells with green fluor-
escence under fluorescence microscopy were observed
(Figure 2). Expressions of MACC1 in stably transfected
cells, which were selected by G418, were measured by
RT-PCR and Western blot. Compared to control cells,
levels of MACC1 mRNA and protein were significantly
down-regulated in OVCAR-3-s1, OVCAR-3-s2 and
OVCAR-3-s3 cells, especially in OVCAR-3-s3 cells
(Figure 3). According to these results, OVCAR-3-s3 cells
which showed the highest inhibitory rate of MACC1
were used for further assay described below.
Inhibition of cell proliferation and colony formation by
MACC1 RNAi
According to Figure 4, the proliferation of OVCAR-3-s3
cells was obviously inhibited from the second day, when
compared with control cells. There were no differences
among OVCAR-3, OVCAR-3-neo and OVCAR-3-NC
cells. In addition, OVCAR-3-s3 cells had lower rate of
colony formation than control groups as shown in
Figure 5. Thus, knockdown of MACC1 by RNAi could
inhibit the growth of ovarian carcinoma cells.
Apoptosis induced by MACC1 RNAi
Cell apoptosis rate measured by flow cytometer (Figure 6)
in OVCAR-3-s3 cells was markedly increased to 24.13%,
higher than 3.37% for OVCAR-3, 7.82% for OVCAR-3-
neo, and 7.19% for OVCAR-3-NC cells (P < 0.05). Further-
more, TUNEL assay showed numbers of apoptosis body
were increased in OVCAR-3-s3 cells (Figure 7). The
results of apoptosis assay indicated the inhibitory effect of
cell growth might due to the enhancement of apoptosis by
MACC1 RNAi.
Suppression of migration by MACC1 RNAi
Compared with control groups, OVCAR-3-s3 cells
showed suppressed capacity of impaired migration
(Figure 8 and 9). Moreover, numbers of cell adherent on
lower membranes of transwell chamber were sharply
decreased in OVCAR-3-s3 group, which were shown in
Table 1 Expressions of MACC1 protein in different ovarian tissues analyzed by immunohistochemistry
Tissue type Variable n Positive n Positive rate (%)
Normal ovarian tissue - 20 1 5.0
Benign ovarian tumor serous 10 2 15.8
mucous 9 1
Age (years) < 50 12 8
≥50 40 30
FIGO stage I/II 5/11 3/5
III/IV 24/12 19/11
Histological type Serous 30 21
Ovarian carcinoma tissue Mucous 22 17
Histological grade G1 10 4
G2/G3 14/28 9/25
Ascites No 24 16
Yes 28 22
Lymph nodes metastasis No 32 20
Yes 20 18 73.1*
* c
2 test. Compared with normal ovarian and benign ovarian tumor tissues P < 0.05.
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Page 4 of 12Figure 1 Immunohistochemistry analysis of MACC1 expression in different ovarian tissues. Normal ovary (A) and benign ovarian tumor
(B) showed a lower staining of MACC1, but ovarian cancer (C) showed higher density staining (DAB staining, × 400). (D): Bar graphs show the
positive rates of MACC1 protein. *P < 0.05 versus normal and benign ovarian tissues.
Figure 2 Transfection of MACC1-shRNA into ovarian carcinoma OVCAR-3 cells. (A): Normal OVCAR-3 cells under incandescent light (× 200).
(B): After transfection 24 h, OVCAR-3-s3 cells under fluorescent light (× 100). (C): Monoplast colony of OVCAR-3-s3 cells selected by G418 for
three weeks (× 200). (D): G418 resistant OVCAR-3-s3 cell line (× 100).
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suppress migration capability of ovarian carcinoma cells.
Activity of invasion retarded by MACC1 RNAi
The numbers of cell, assessed in Matrigel invasion
assay, were remarkably decreased in OVCAR-3-s3 group
(Figure 11). On the other hand, the volumes of xenograft
tumors removed from nude mice were retarded apparently
in OVCAR-3-s3 group after 35 days. As shown in Figure
12, the growth of xenograft tumors in OVCAR-3-s3 group
obviously fell behind other groups. Results of invasion assay
indicated invasive potential of ovarian carcinoma cells
could be retarded by MACC1 RNAi.
Down-regulation of Met and MEK/ERK pathways activity
by MACC1 RNAi
Expressions of Met, MEK1/2, p-MEK1/2, ERK1/2,
p-ERK1/2, Akt and p-Akt were measured by Western
blot in OVCAR-3, OVCAR-3-neo, OVCAR-3-NC and
OVCAR-3-s3 cells. As a result of MACC1 knockdown,
significant reductions of Met and p-MEK1/2 and
p-ERK1/2 expression were observed in OVCAR-3-s3
cells. However, none obvious changes were detected on
levels of total MEK1/2, total ERK1/2, total Akt and p-Akt
(Figure 13 and 14). In addition, expressions of cyclinD1
and MMP2 decreased, level of cleaved caspase3 was
increased after MACC1 inhibition (Figure 15).
Discussion
Among gynecological cancers, more than 75% of ovarian
carcinoma patients are suffered with advanced disease,
and the majority will relapse and die of their disease
[11,12]. Despite major efforts in diagnosis and improve-
ments in the treatment of epithelial ovarian cancer, cur-
rent therapies for advanced ovarian cancer are not
effective enough and total survival rate of subjects with
ovarian carcinoma has not changed appreciably.
MACC1 is closely associated with several types of can-
cer, and can serve as poor prognosis and metastatic
Figure 3 Down-regulation of MACC1 by MACC1-shRNA in ovarian carcinoma cells. The best inhibitory effects of MACC1 were identified in
OVCAR-3-s3 cells by RT-PCR (A) and Western blot (C), which were both performed for three times independently. Bar graphs show the relative
expression levels of MACC1 mRNA (B) and protein (D).*P < 0.05 versus control groups.
Figure 4 Suppression of proliferation by MACC1 RNAi in
ovarian carcinoma cells measured by MTT assay. Obviously
inhibitory effect of cell proliferation was observed from the second
day after MACC1 knockdown.*P < 0.05 versus control groups.
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Page 6 of 12Figure 5 MACC1-shRNA inhibited the monoplast colony formation of ovarian carcinoma cells. Monoplast colony in 50-cells wells of each
group. (A): OVCAR-3 cells. (B): OVCAR-3-neo cells. (C): OVCAR-3-NC cells. (D): OVCAR-3-s3 cells (Hematoxylin staining, × 100). Bar graphs show the
average rates of monoplast colony formation.*P < 0.05 versus control groups.
Figure 6 Apoptosis induced by MACC1 RNAi in ovarian carcinoma cells. After MACC1 inhibition, cell apoptosis was obviously induced in
ovarian carcinoma cells measured by flow cytometry assay.
Figure 7 MACC1-shRNA increased the apoptosis rate of ovarian carcinoma cells. TUNEL assay was used to measure the apoptosis rate in
OVCAR-3 cells (A), OVCAR-3-neo cells (B), OVCAR-3-NC cells (C), and OVCAR-3-s3 cells (D). DAB staining, × 400. Bar graphs show the rates of
apoptosis.*P < 0.05 versus control groups.
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cer, and hepatocellular carcinoma [5-8]. In this study, we
detected high levels of MACC1 in ovarian cancer tissues
by immunohistochemistry, which showed abnormal
expression of MACC1 might be associated with ovarian
carcinoma. However, the relations between abnormal
expression of MACC1 and ovarian carcinoma had not yet
been reported.
Thus, we designed and synthesized three specific
shRNAs against MACC1 gene to investigate the effects
of MACC1 inhibition on ovarian carcinoma OVCAR-3
cells in present study. Results of RT-PCR and Western
blot showed specific MACC1-shRNAs could effectively
knockdown expression of MACC1 in OVCAR-3 cells.
We also successfully obtained OVCAR-3 cell line with
the best inhibitory effects of MACC1 expression for
further analysis. As a consequence of MACC1 gene
knockdown, the proliferation, migration and invasion of
OVCAR-3 cells were obviously inhibited, but the apop-
tosis rate was significantly increased. These results
showed inhibition of MACC1 could suppress the growth
and metastatic potential of ovarian carcinoma cells in
vitro and in vivo, which suggested MACC1 might impli-
cate in the growth and metastasis of ovarian carcinoma.
MACC1 binds to a 60 bp proximal fragment of endo-
genous MET promoter, where contains a specific Sp1
binding site which is essential for MACC1-induced acti-
vation of MET and subsequent HGF/Met signaling con-
sequences [13]. Once activated, Met can result in
activation of several downstream signaling cascades, such
as MAPK and PI3K/Akt pathways [14]. MACC1 protein
contains several domains which can participate in MAPK
signaling, and MACC1 can be up-regulated by MAPK
pathway which has been identified to be essential for
HGF-induced scattering [15-17]. In colon cancer cells,
MAPK signaling could be hyperactive by transfection of
MACC1, and HGF-induced cell scattering mediated by
MACC1 could be abrogated by MEK specific inhibitors,
whereas not by PI3K specific inhibitors [2].
After inhibition of MACC1 by RNAi in ovarian carci-
noma OVCAR-3 cells, we observed that level of Met
protein was down-regulated significantly, as well as
expressions of p-MEK1/2 and p-ERK1/2 protein, but
expression of p-Akt was uninfluenced. Therefore, we
presumed that inhibition of MACC1 by RNAi might
suppress the malignant behavior of ovarian carcinoma
cells via HGF/Met and MEK/ERK pathways, at least in
Figure 8 Knockdown of MACC1 by RNAi suppressed the migration ability of ovarian carcinoma cells. Wound healing assay was used for
monolayer cell migration assay (Hematoxylin staining, × 100).
Figure 9 Bar graph of the wound healing assay. Each bar
represents the value of wound healing assay. *P < 0.05 versus
control groups.
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and decreased levels of cyclinD1 and MMP2 protein
were detected in ovarian carcinoma cells after RNA
interference against MACC1, which suggested cyclinD1,
caspase3 and MMP2 should be associated with MACC1
mediated downstream signaling.
HGF/Met signaling plays an important role in cellular
growth, epithelial-mesenchymal transition, angiogenesis,
cell motility, invasiveness and metastasis [18]. Deregu-
lated HGF/C-met signaling has been observed in many
tumors, including ovarian carcinoma, and been proved
to contribute to tumor dissemination and metastasis
[19]. MAPK and PI3K/Akt pathways have been demon-
strated to implicate in cell survival, anti-apoptosis, inva-
sion, metastasis and angiogenesis of malignancies,
including ovarian carcinoma [20-22]. Because of these
cascades play key roles in carcinogenesis, some specific
antibodies and small molecules to neutralize or block
the key regulators of these pathways have been used to
inhibit tumor growth and metastasis, which exploit
effective intervention strategies for malignancies
[19,23,24]. According to previous reports and the results
described above, we considered that MACC1, as a key
regulator and upstream signaling of these pathways,
Figure 10 Inhibition of MACC1 by RNAi suppressed the migration ability of ovarian carcinoma cells. Transwell migration assay was used
for cell migration ability assay. (A): OVCAR-3 cells. (B): OVCAR-3-neo cells. (C): OVCAR-3-NC cells. (D): OVCAR-3-s3 cells (Hematoxylin staining, ×
400). Each bar represents the cell numbers adherent on lower membrane.*P < 0.05 versus control groups.
Figure 11 Inhibition of invasion by MACC1 RNAi in ovarian carcinoma cells. Cell invasive ability was assessed by Matrigel invasion assay.
(A): OVCAR-3 cells. (B): OVCAR-3-neo cells. (C): OVCAR-3-NC cells. (D): OVCAR-3-s3 cells (Hematoxylin staining, × 400). Each bar represents the cell
numbers adherent on lower membrane.*P < 0.05 versus control groups.
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cancer.
Conclusions
In summary, our data showed that MACC1 might impli-
cate in growth and metastasis of ovarian carcinoma. In
ovarian carcinoma cells, the antitumor effects of
MACC1 RNAi might involve in the inhibition of HGF/
Met and MEK/ERK pathways. As a key regulator of
HGF/Met signaling, RNA interference against MACC1
could serve as a promising intervention strategy for
gene therapy of ovarian carcinoma.
Figure 12 Xenograft tumor growth of ovarian carcinoma cells was retarded by MACC1 RNAi. On the 35th day, volumes of subcutaneous
tumor in OVCAR-3-s3 group were remarkably smaller than those of control groups. Line curves represent the tumor volumes of xenograft
models. *P < 0.05 versus control groups.
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